Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2801 to 2850 of 3807 results for treatment

  1. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  2. Further research is recommended to help address remaining clinical and cost-effectiveness uncertainties for esketamine, summarised in section 3.36 .

    assessment and decision modelling • the natural history and long-term course of treatment-resistant depression and health-related...

    Research recommendation
    Published
    6 January 2023

  3. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (HTG315)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

    HealthTech guidance
    Published
    7 August 2013
    View recommendations

    Sections for HTG315

  4. Smart Peak Flow for monitoring asthma (MIB282)

    NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .

    Medtech innovation briefing
    Published
    11 January 2022

  5. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)

    This guidance has been updated and replaced by NICE technology appraisal guidance 527.

    Withdrawn guidance

  6. Non-rigid stabilisation techniques for the treatment of low back pain (IPG183)

    This guidance has been updated and replaced by NICE HealthTech guidance 239.

    Withdrawn guidance

  7. Non-rigid stabilisation techniques for the treatment of low back pain (IPG366)

    Interventional procedures, IPG366 - Issued: November 2010 --> We have moved interventional procedures guidance 366 to become HealthTech guidance 239. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Radiofrequency ablation for the treatment of colorectal metastases in the liver (IPG92)

    This guidance has been updated and replaced by NICE HealthTech guidance 208.

    Withdrawn guidance

  9. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    agreed that hypothyroidism needs thyroid hormone replacement. Potential treatments are levothyroxine, usually prescribed to everyone,...

    Research recommendation
    Published
    10 February 2020

  10. Sustainability

    NICE is committed to supporting the national agenda for achieving a sustainable health and care system.

  11. Living-donor lung transplantation for end-stage lung disease (HTG111)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    HealthTech guidance
    Published
    24 May 2006
    View recommendations

    Sections for HTG111

  12. Comprehensive assessment versus a brief assessment:- For people with a suspected common mental health disorder, what is the clinical and cost effectiveness of using a comprehensive assessment (conducted by mental health professional) versus a brief assessment (conducted by a paraprofessional)?

    remains about the accuracy and consequent identification of appropriate treatment by paraprofessionals in primary care. An assessment by...

    Research recommendation
    Published
    9 June 2015

  13. Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents (TA13)

    This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].  

    Withdrawn guidance

  14. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Withdrawn guidance

  15. Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

    This guidance has been updated and replaced by NICE technology appraisal guidance 439.

    Withdrawn guidance

  16. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  17. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)

    We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  18. Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

    We have moved medical technologies guidance 6 to become HealthTech guidance 268. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  19. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  20. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

    Withdrawn guidance

  21. Epidurals:- What is the clinical and cost effectiveness of image-guided compared with non-image-guided epidural injections for people with acute sciatica?

    notes(if applicable) Why this is important:- Epidural injection of treatments, including corticosteroids, is commonly offered to people...

    Research recommendation
    Published
    13 February 2017

  22. Care pathway:- In the UK, what is the optimal care pathway for young people and adults with coexisting severe mental illness and substance misuse?

    important:- There is a lack of published evidence on care pathways on treatment, management and follow-up of people with coexisting...

    Research recommendation
    Published
    10 February 2017

  23. NICE encourages further research on laparoscopic gastric plication for severe obesity, which should include information about long-term efficacy and safety, and specifically how the procedure influences further gastric surgery. Comparison with alternative procedures would be useful.

    efficacy of the procedure. Therefore, laparoscopic gastric plication for the treatment of severe obesity should only be used with...

    Research recommendation
    Published
    9 June 2015

  24. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    April 2026: This Medtech innovation briefing has been withdrawn because the L-Dex U400 device is no longer available in the UK.

    Withdrawn advice

  25. For people with alcohol dependence, which medication is most likely to improve adherence and thereby promote abstinence and prevent relapse?

    are still clinically and cost effective. Retaining more service users in treatment could further significantly improve outcomes for...

    Research recommendation
    Published
    9 June 2015

  26. Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (HTG411)

    Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.

    HealthTech guidance
    Published
    27 April 2016
    View recommendations

    Sections for HTG411

  27. Undisplaced intracapsular hip fractures: For people with undisplaced (or non-displaced) intracapsular hip fracture, what features should be used to characterise the injury and what are the optimal clinical and cost-effective management strategies?

    recognised, resulting in some people not being offered the most appropriate treatment. Research is needed to help healthcare...

    Research recommendation
    Published
    3 February 2023

  28. What is the clinical effectiveness and safety of differing doses of lipid-modifying therapy in children with FH?

    concentration in treated children with FH receiving lipid-modifying drug therapy. Treatment is recommended from 10 years onwards,...

    Research recommendation
    Published
    15 November 2019

  29. Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification when selecting which people with CUADT would benefit from short- or long-term enteral nutrition?

    diagnosis for people who need enteral nutrition support during curative treatment. Variation across the UK exists as a result of...

    Research recommendation
    Published
    6 April 2016

  30. An instrument to measure quality of life in people with glaucoma:- What instrument should be used to measure health related quality of life in people with glaucoma?

    is important:- Quality of life is the most important overall measure of treatment effect for patients as it measures their life...

    Research recommendation
    Published
    18 October 2018

  31. Long-term outcomes of pharmacological and uterine-sparing surgical treatments for HMB associated with adenomyosis:- What are the long-term clinical outcomes of pharmacological and uterine-sparing surgical treatments in women with HMB associated with adenomyosis?

    impact of adenomyosis on symptoms of HMB or the best treatment for this condition. Optimising treatment can lead to better...

    Research recommendation
    Published
    14 November 2018

  32. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention (TA182)

    This guidance has been replaced by NICE technology appraisal guidance 317.

    Withdrawn guidance

  33. Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety (TA51)

    This guidance has been updated and replaced by NICE technology appraisal guidance 97.

    Withdrawn guidance

  34. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Withdrawn guidance

  35. HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)

    NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .

    Medtech innovation briefing
    Published
    13 July 2021

  36. FRAX and QFracture in adults receiving bone protective therapy:- What is the utility of FRAX and QFracture in adults receiving bone protective therapy?

    at the end of this treatment period is important, since some people remain at high risk of fracture and require continued...

    Research recommendation
    Published
    9 June 2015

  37. Non-invasive tests for diagnosing NASH:- Which non-invasive tests most accurately identify non-alcoholic steatohepatitis (NASH) in people with non-alcoholic fatty liver disease (NAFLD)?

    morbidity and mortality. As a result, NASH has been the main target for treatment in NAFLD. This is because reducing the severity of...

    Research recommendation
    Published
    24 August 2016

  38. Assessment models for different groups of children and young people:- How effective are the models currently used for assessing the needs of, and level of risk for, children and young people from different population groups who display harmful sexual behaviour?

    basis for needs assessment and decisions about therapeutic interventions, treatment placements and care plans.For those in the criminal...

    Research recommendation
    Published
    17 October 2016

  39. How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period?

    explanatory notes(if applicable) Drugs are effective for the acute treatment of bipolar disorder and for preventing relapse. All drugs...

    Research recommendation
    Published
    13 July 2017

  40. Cystourethrogram: How accurate is the first CT scan with contrast (trauma scan) for detecting bladder injuries in people with suspected bladder injuries after a traumatic incident?

    diagnose non‑bladder injuries. People who do not have injuries needing urgent treatment may then either be given another CT scan or a...

    Research recommendation
    Published
    12 December 2022

  41. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  42. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  43. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

    HealthTech guidance
    Published
    20 August 2014
    View recommendations

    Sections for HTG348

  44. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Withdrawn guidance

  45. Laser in situ keratomileusis (LASIK) for the treatment of refractive errors (IPG102)

    This guidance has been replaced by NICE interventional procedure guidance 164.

    Withdrawn guidance

  46. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  47. Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)

    This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.

    Withdrawn guidance

  48. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

    Withdrawn guidance

  49. Cystourethrogram:- How accurate is the first CT scan with contrast (trauma scan) for detecting bladder injuries in people with suspected bladder injuries after a traumatic incident?

    diagnose non-bladder injuries. People who do not have injuries needing urgent treatment may then either be given another CT scan or a...

    Research recommendation
    Published
    21 March 2016

  50. Primary versus secondary stenting for treating people with critical limb ischaemia caused by disease of the infra-geniculate arteries:- What is the clinical and cost effectiveness of selective stent placement compared with angioplasty plus primary stent placement for treating people with critical limb ischaemia caused by disease of the infra-geniculate arteries?

    endovascular treatment. Infra-geniculate disease is more complex to treat by endovascular means, and the risks and benefits of different...

    Research recommendation
    Published
    9 June 2015